CONTINUOUS CIRCULATION OF DENV-3 GENOTYPE 3 IN DELHI : A SINGLE

HOSPITAL BASED SURVEILLANCE STUDY

Abhishek Padhi[1], Ekta Gupta[1], Gaurav Singh[1], Shama Parveen[2], Arshi Islam[2], Bansidhar

Tarai[3]

[1] Department Of Clinical Virology, Institute Of Liver And Biliary Sciences, New Delhi

[2] Centre For Interdisciplinary Research In Basic Sciences, Jamia Millia Islamia, New Delhi

[3] Department Of Microbiology And Infection Control, Max Superspeciality Hospital, Saket,

New Delhi

CORRESPONDING AUTHOR

Dr. Ekta Gupta

Professor and Head

Department Of Clinical Virology,

Institute Of Liver And Biliary Sciences, New Delhi

Email ID : ektagaurisha@gmail.com

ABSTRACT

BACKGROUND

Delhi is hyperendemic for dengue virus (DENV) where all the four DENV have been

previously reported. A constant vigilance of circulating dengue virus serotypes is important

in surveillance, since the introduction of a new variant to areas affected by pre-existing

serotypes constitutes a risk factor for DHF and Dengue Shock Syndrome.

OBJECTIVES

This retrospective study was carried out with an objective to determine the circulating

serotype and genotype of Dengue virus in acute phase blood samples of patients who

reported to a tertiary liver care hospital in New Delhi during the last two years (2017 – 2018).

METHODS

The data of clinician-initiated testing for dengue NS1 antigen was searched in the

institutional hospital information system. The serum sample of dengue NS1 antigen positive

cases confirmed by ELISA (PANBIO, Gyeonggi-do, ROK) and a fever duration of less than

5 days were retrieved from the laboratory archive. The dengue virus serotyping on these

sample were carried out by reverse transcriptase PCR. Sequencing and phylogenetic analysis

was done for the capsid-pre membrane (CPrM) region to determine the genotype.

RESULTS

A total of 440 acute-phase samples were received. Twenty one(4.77%) were positive

for dengue NS1 antigen with a mean age of 35.1 years and male to female ratio of

1.1:1. Eight cases (38.09%) were positive by Dengue RT-PCR and all belonged to DENV-3

serotypes. Phylogenetic tree analysis revealed DENV-3 clustered to genotype III with 100%

homology with 2008 Indian subcontinent strain.

CONCLUSION

This study revealed that the present circulating dengue virus serotype in Delhi is DENV–3

genotype III. It is similar to previously isolated 2008 Indian subcontinent strain suggesting

neither any change in serotype nor any further evolution of DENV-3. That explains the

present relatively stable dengue endemicity in Delhi NCR.

Key words : Dengue, DENV 3, Genotype 3, Surveillance

INTRODUCTION

Dengue is a vector borne acute arboviral infection widely prevalent in the tropics and sub tropics. According to the World Health Organization (WHO) estimates, 3.6 billion people reside in dengue endemic areas and 70 % of the actual burden is in Asia (1)(2). Symptoms of dengue infection is wide ranging from subclinical disease to severe flu like symptoms, and some people develop severe dengue associated with number of complications such as severe bleeding, organ impairment and/or plasma leakage. Over the past two decades the burden of dengue cases has increased almost 15 folds (1).

Dengue infection is caused by a virus belonging to the family *Flaviviridae,* genus *Flavivirus* and consists of a single stranded positive sense RNA about 11 kb as its genome and encodes for three structural {capsid (C), pre-membrane (prM) and envelope (E)} and 7 non-structural proteins (3) . Dengue virus (DENV) can be classified into four antigenically distinct serotypes (DENV-1, DENV-2, DENV-3, DENV-4) based on sequence diversity and each serotype is further grouped into various genotypes (4).

A lifelong immunity is attained after infection with a particular serotype and a cross protective immunity against other serotypes for a short period of time (5). Secondary infection by a different serotype is associated with severe dengue probably due to antibody-dependent enhancement (ADE) resulting in high viremia (6) (7).

Delhi is hyperendemic for DENV with co-circulation of all the four dengue serotypes (8) . Delhi has witnessed a number of dengue epidemics in the past two decades due to rapid boom in urbanization, monsoon influenced subtropical climate, water storage practices and use of water coolers. These factors provide the mosquito vector *Aedes aegypti* a favourable environment to thrive and transmit DENV amongst the human population which at times

gives rise to major outbreaks depending upon the circulating serotype and genotype of DENV

(9) (10).

In the absence of an effective vaccine, virological surveillance and development of effective,

locally adapted control programmes are the two most important arms in the prevention of

dengue infection. Hence, there is a need of continuous monitoring of the circulating DENV

type in a given population to develop such locally adapted control programmes. Furthermore

most studies focus on the circulating serotypes during epidemics and the studies on

circulating strains during the interepidemic periods are neglected and there can be significant

variations for which public health systems are unprepared (11).

We carried out the present study targeting the *CprM* gene junction to elucidate the molecular

epidemiology of the circulating strain of DENV in the population of Delhi post 2015 dengue

epidemic.

<u>MATERIAL AND METHODS</u>

Patient selection and specimen collection

This was a retrospective study carried out from January 2017 to December 2018 in a tertiary

care liver hospital in New Delhi, India. All consecutive patients with signs and symptoms

(according to WHO guidelines) suggestive of DENV infections visiting the OPD or admitted

in IPD were tested for DENV infection (12) . Plasma was separated from blood samples and

stored in the virology repository at -80 °C till further testing.

DENV diagnosis

Diagnosis of DENV was done with Dengue NS1 Ag (PANBIO ,Gyeonggi-do, ROK) if the

sample was collected within the first 5 days of onset of clinical symptoms, and with Dengue

IgM capture ELISA (PANBIO ,Gyeonggi-do, ROK) if the sample was collected after 5 days

of onset of clinical symptoms.

RNA extraction and cDNA synthesis

All the DENV NS1 Ag-positive cases were further processed for RNA extraction using

QIAamp Viral Mini kit (Qiagen,GmBH, Germany) according to the manufactures'

instructions. The extracted viral RNA was reverse transcribed to cDNA using Quantitect

reverse transcriptase kit (QIAGEN, GmBH Germany) according to manufacturer's

instructions.

Detection of DENV by RT-PCR

The cDNA was then amplified in the external round of RT-PCR using dengue virus

consensus primers (D1: 5' TCAATATGCTGAAACGCGCGAGAAACC G 3'; D2: 5'

TTGCACCAACAGTCAATGTCT TCA GGT TC 3') in 25 µl reaction volume. The DNA

product obtained was of 511 bp.

Subsequent amplification of cDNA was carried out with the dengue virus consensus forward

primer (D1) and four dengue serotype-specific reverse primers (TS 1: 5'

CGTCTCAGTGATCCGGGGA 3'; TS 2: 5' CGCCACAAGGGCCATGAACAG 3'; TS 3:

5' TAACATCAT- CATGAGACAGAGC 3'; TS 4: 5'CTCTGTTGTCTTAAACAAGAGA

3') as described by Lanciotti *et al* [13], but all the 4 serotype-specific primers were added in a

single reaction mixture. A 1 : 20 dilution of the external PCR product was used in the nested

PCR reaction. Dengue virus serotypes were identified by the size of the resulting DNA bands

(DENV 1–482 bp, DENV 2–119 bp, DENV 3–290 bp, DENV 4–392 bp). Amplicons were

resolved on 2% agarose gel and visualized with ethidium bromide in UV light by using a gel

documentation system (Wealtec, USA).

DNA Sequencing

PCR amplicons were gel-purified using QIAquick gel extraction kit (QIAGEN, GmBH

Germany) as per manufacturer's instructions. Purified amplicons were subjected to Sanger

sequencing using ABI 3730 DNA analyzer (Thermofisher Scientific, MA, Waltham).

Phylogenetic analysis

Identity of the obtained sequences were confirmed by BLAST tool available at NCBI

(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Both forward and reverse sequences were manually

aligned and edited to resolve the nucleotide ambiguities and to obtain consensus sequence

using GeneDoc v.2.7 (http://genedoc. software.informer. com/2.7/) and BioEdit v.7.2

(http://bioedit.software.informer.com/ 7.2/). The study sequences were aligned with other

available sequences retrieved from Genbank using CLUSTAL X2 (http://

www.clustal.org/clustal2/) achieved in BioEdit v.7.2 (http://bioedit.

software.informer.com/7.2/). All the new sequences of DENV-3 genome were submitted to

Genbank.

The phylogenetic tree was constructed for the DENV-3 sequences by Maximum Likelihood

method using algorithms implemented in MEGA6 v.6.06 software. Genetic distances were

calculated using Tamura-Nei model of nucleotide substitution. The robustness of the tree was

assessed with 1000 bootstrap replicates.

ETHICS

The study was approved by the Institutional ethics committee (IEC) of Institute of Liver and

Biliary Sciences (ILBS) and patient consent form was waived off because of the use of

leftover clinical samples sent to virology laboratory for routine diagnosis for DENV.

RESULTS

A total of 440 acute-phase samples were received. Twenty one(4.77%) were positive

for dengue NS1 antigen with a mean age of 35.1 years and male to female ratio of

1.1:1. Eight cases (38.09%) were positive by Dengue RT-PCR and all belonged to DENV-3

serotypes. No case of concomitant infection with more than one serotype was observed. In

cases where NS1 antigen was positive but RT-PCR was negative, duration of fever was 5

days, as by this time viremia declines and only NS1 antigen persists till IgM antibodies are

formed.

DNA sequence analysis

The CprM region of the DENV-3 genome was sequenced for 8 positive samples. The

samples were sequenced in both forward and reverse direction. All the obtained DENV-3

sequences were confirmed by BLAST. These sequences were submitted in Genbank database

and accession number of the same are awaited.

Phylogenetic analysis

Phylogenetic analysis of DENV-3 serotype was carried out for the present investigation. The

H87 strain of genotype V of DENV-3 (GenBank Accession number M93130) was used as the

proto- type strain. The aligned region was 240bp that corresponds to 131 to 370bp of the

CprM region of full genome the prototype strain. Eighty sequences (8 studied and 72 other

sequences of different genotypes of DENV-3 (GenBank) were aligned to construct Maximum

161   Likelihood tree. Phylogenetic analysis clustered all the studied sequences with the genotype

162   III (Indian subcontinent).

Maximum likelihood phylogenetic tree of DENV-3 strains. The study sequences are marked by the symbol Δ. Bootstrap values are represented by the number on nodes generated by 1000 replications. The strains used to construct the tree are represented by the strain name, followed by country/region and year of isolation/submission of strain. The study sequences clustered with Genotype III (Indian subcontinent).

DISCUSSION

Delhi, the capital of India is known to be hyperendemic for DENV infection due to the

circulation of all the four serotypes in the population (10). In the past two decades Delhi has

witnessed several outbreaks and epidemics of DENV infection. Dense human population,

rapid urbanization, increasing globalization and the tropical climatic conditions have

contributed towards the frequent outbreaks of DENV infection in Delhi. Hence, a continuous

sero-surveillance of the circulating DENV strain is a necessity to prevent further epidemics

and help in the development of local control program (14) .

In the present study, molecular characterization of circulating DENV strains was carried out

targeting the *CprM* junction. Genotyping based on *CprM* junction is easier and economical

because of the utilisation of a single set of primer for both amplification and sequencing of

any of the four DENV serotypes (9).

A change in the circulation pattern of Dengue serotypes has been reported from Delhi in

terms of prevalent serotype. The DENV-2 serotype dominated the Dengue fever during 2003

to 2006 (15)(16) (17)(18)(19). DENV-3 emerged as a dominant serotype in the year 2003

which continued in circulation till 2006 (15). In addition, 2006 also reported the emergence

of DENV-1 in 30% of the cases (15) . Subsequently, the predominance of DENV-1 was

reported till 2010 . DENV-1 and DENV-2 serotypes co-circulated in almost equal proportions

in 2011 [8]. A switch in the prevailing serotype occurred again in 2012 due to co-dominant

circulation of DENV-2 and DENV- 3. DENV-2 dominated during 2012, 2013 and 2015

[8,15]. Subsequently, DENV-1 dominated in 2014 [16]. Further, during 2016 a change in the

circulating serotype occurred leading to dominance of DENV-3 in this region.

YEAR	DENV SEROTYPE	EPIDEMIC/ NON	REFERENCES

		EPIDEMIC	
1996	2	Epidemic	Dar et al (20)
1997	1	Non epidemic	Vajpayee et al(21)
2003	1,2,3(Genotype III),4	Epidemic	Gupta et al (8)
2004	1	Non epidemic	Gupta et al(22)
2005	3(Genotype III)	Epidemic	Gupta et al(22)
2006	3(Genotype III)	Epidemic	Bharaj et al (23)
2007	3(Genotype III)	Non epidemic	Kukreti et al (15)
2008	1	Non epidemic	Chakravarti et al (24)
2010	1	Non epidemic	Gupta et al (25)
2011-2014	1,2,3(Genotype III)	Non epidemic	Afreen et al (26)
2015	2	Epidemic	Choudhary et al(27)
2016	3(Genotype III)	Non epidemic	Parveen et al(28)
2017-2018	3(Genotype III)	Non epidemic	Present study

Table 1 : Circulation of various dengue serotypes in Delhi

The most relevant finding of our study was the circulation of a single serotype, DENV-3

genotype III during 2017-2018 which was similar to the DENV-3 strain circulating in the

year 2016 (28). Similar studies from Pakistan also reported the circulation of DENV-3 during

2015 (29). Studied strains of DENV-3 were clustered in Genotype III (Indian subcontinent)

by phylogenetic analysis. The analysis also concluded that the DENV-3 study sequences

grouped with the strains from China (unpublished), Pakistan (30) and India (30) (31) (32) .

Furthermore DENV-3 serotype has been reported from different geographical regions

including India.

The oldest DENV-3 strain, Philippines 56, was classified as genotype I along with other

strains from the Philippines and Indonesia isolated over two decades, suggesting the

persistence of this genotype in the area for a long time.

It is evident that genotype III of DENV-3 circulates throughout the world, whereas other

genotypes are localized in particular geographic regions. This indicates a higher potential of

genotype III to spread and dominate in geographically diverse regions of the world. This

genotype has also been implicated in major dengue epidemics in several parts of Asia, Africa

and the Americas and has the potential to cause an international dengue pandemic (33).

Furthermore our study also shows that in the non-epidemic period usually one strain

circulates and co-circulation of multiple types with concurrent infection with more than one

serotype is not seen.

CONCLUSION

The findings of this study indicate continuous circulation of DENV-3, genotype III, since

2003 in Delhi. DENV-3, Genotype III has a potential to cause global pandemic which

warrants a continued surveillance to monitor its incursion and spread for effective control

measures before the onset of the next outbreak. Further studies to understand the host

adaptation mechanisms for vaccine implementation in our population are warranted .

ACKNOWLEDGEMENT

The authors would like to thank Mr. Piyush Bahuguna for his contribution in providing the

data for dengue virus infection for the year 2017-2018.

CONFLICT OF INTEREST

None

FUNDING

None

References :

1.   Dengue and severe dengue [Internet]. [cited 2020 Mar 14]. Available from:

https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue

2.   Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global

distribution and burden of dengue. Nature. 2013 Apr 25;496(7446):504–7.

3.   Dengue infection | Nature Reviews Disease Primers [Internet]. [cited 2020 Mar 14].

Available from:

https://www.nature.com/articles/nrdp201655?draft=collection&proof=true

4.   Chen R, Vasilakis N. Dengue — Quo tu et quo vadis? Viruses. 2011 Sep 1;3(9):1562–

608.

5.   Gubler DJ. The Global Emergence/Resurgence of Arboviral Diseases As Public Health

Problems. Archives of Medical Research. 2002 Jul 1;33(4):330–42.

6.   Guzman MG, Vazquez S. The Complexity of Antibody-Dependent Enhancement of

Dengue Virus Infection. Viruses. 2010 Dec 8;2(12):2649–62.

7.   Grange L, Simon-Loriere E, Sakuntabhai A, Gresh L, Paul R, Harris E. Epidemiological

Risk Factors Associated with High Global Frequency of Inapparent Dengue Virus

Infections. Front Immunol [Internet]. 2014 Jun 11 [cited 2020 Mar 14];5. Available

from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052743/

8.   Dar L, Gupta E, Narang P, Broor S. Cocirculation of dengue serotypes, Delhi, India,

2003. Emerging Infect Dis. 2006 Feb;12(2):352–3.

9.   Kukreti H, Mittal V, Chaudhary A, Rautela RS, Kumar M, Chauhan S, et al. Continued

persistence of a single genotype of dengue virus type-3 (DENV-3) in Delhi, India since

its re-emergence over the last decade. J Microbiol Immunol Infect. 2010 Feb;43(1):53–

61.

10. Gupta E, Dar L, Kapoor G, Broor S. The changing epidemiology of dengue in Delhi,

India. Virol J. 2006 Nov 5;3:92.

11. Gupta E, Mohan S, Bajpai M, Choudhary A, Singh G. Circulation of Dengue virus-1

(DENV-1) serotype in Delhi, during 2010–11 after Dengue virus-3 (DENV-3)

predominance: A single centre hospital based study. :4.

12. Organization WH. Dengue guidelines for diagnosis, treatment, prevention and control:

new edition [Internet]. World Health Organization; 2009 [cited 2020 Mar 14]. Available

from: https://apps.who.int/iris/handle/10665/44188

13. Lanciotti RS, Calisher CH, Gubler DJ, Chang G-J, VORNDAMt AV. Rapid Detection

and Typing of Dengue Viruses from Clinical Samples by Using Reverse Transcriptase-

Polymerase Chain Reaction. J CLIN MICROBIOL. 1992;30:7.

14. Gore MM. Need for constant monitoring of dengue infections. Indian J Med Res. 2005

Jan;121(1):9–12.

15. Kukreti H, Chaudhary A, Rautela RS, Anand R, Mittal V, Chhabra M, et al. Emergence

of an independent lineage of dengue virus type 1 (DENV-1) and its co-circulation with

predominant DENV-3 during the 2006 dengue fever outbreak in Delhi. Int J Infect Dis.

2008 Sep;12(5):542–9.

16.   Lanciotti RS, Calisher CH, Gubler DJ, Chang G-J, VORNDAMt AV. Rapid Detection

and Typing of Dengue Viruses from Clinical Samples by Using Reverse Transcriptase-

Polymerase Chain Reaction. J CLIN MICROBIOL. 1992;30:7.

17.   Dash PK, Parida MM, Saxena P, Kumar M, Rai A, Pasha ST, et al. Emergence and

continued circulation of dengue-2 (genotype IV) virus strains in northern India. J Med

Virol. 2004 Oct;74(2):314–22.

18.   Singh P, Mittal V, Rizvi MMA, Chhabra M, Sharma P, Rawat DS, et al. The first

dominant co-circulation of both dengue and chikungunya viruses during the post-

monsoon period of 2010 in Delhi, India. Epidemiol Infect. 2012 Jul;140(7):1337–42.

19.   Singh UB, Maitra A, Broor S, Rai A, Pasha ST, Seth P. Partial nucleotide sequencing

and molecular evolution of epidemic causing Dengue 2 strains. J Infect Dis. 1999

Oct;180(4):959–65.

20.   Dar L, Broor S, Sengupta S, Xess I, Seth P. The first major outbreak of dengue

hemorrhagic fever in Delhi, India. Emerg Infect Dis. 1999;5(4):589–90.

21.   Vajpayee M, Mohankumar K, Wali JP, Dar L, Seth P, Broor S. Dengue virus infection

during post-epidemic period in Delhi, India. Southeast Asian J Trop Med Public Health.

1999 Sep;30(3):507–10.

22.   Gupta E, Dar L, Kapoor G, Broor S. The changing epidemiology of dengue in Delhi,

India. Virol J. 2006 Nov 5;3:92.

23.   Bharaj P, Chahar HS, Pandey A, Diddi K, Dar L, Guleria R, et al. Concurrent infections

by all four dengue virus serotypes during an outbreak of dengue in 2006 in Delhi, India.

Virol J. 2008 Jan 9;5:1.

24.   Chakravarti A, Kumar A, Matlani M. Displacement of dengue virus type 3 and type 2

297   by dengue virus type 1 in Delhi during 2008. Indian J Med Microbiol. 2010

298   Dec;28(4):412.

299   25.   Gupta E, Mohan S, Bajpai M, Choudhary A, Singh G. Circulation of Dengue virus-1

300   (DENV-1) serotype in Delhi, during 2010–11 after Dengue virus-3 (DENV-3)

301   predominance: A single centre hospital based study. :4.

302   26.   Afreen N, Naqvi IH, Broor S, Ahmed A, Parveen S. Phylogenetic and Molecular Clock

303   Analysis of Dengue Serotype 1 and 3 from New Delhi, India. PLoS ONE.

304   2015;10(11):e0141628.

305   27.   Choudhary MC, Gupta E, Sharma S, Hasnain N, Agarwala P. Genetic signatures

306   coupled with lineage shift characterise endemic evolution of Dengue virus serotype 2

307   during 2015 outbreak in Delhi, India. Trop Med Int Health. 2017 Jul;22(7):871–80.

308   28.   Parveen N, Islam A, Tazeen A, Hisamuddin M, Abdullah M, Naqvi IH, et al.

309   Circulation of single serotype of Dengue Virus (DENV-3) in New Delhi, India during

310   2016: A change in the epidemiological trend. Journal of Infection and Public Health.

311   2019 Jan 1;12(1):49–56.

312   29.   Suleman M, Faryal R, Alam MM, Khurshid A, Sharif S, Shaukat S, et al. Outbreak of

313   dengue virus type-3 in Malakand, Pakistan 2015; A laboratory perspective. Acta Trop.

314   2017 May;169:202–6.

315   30.   Koo C, Nasir A, Hapuarachchi HC, Lee K-S, Hasan Z, Ng L-C, et al. Evolution and

316   heterogeneity of multiple serotypes of Dengue virus in Pakistan, 2006–2011. Virology

317   Journal. 2013 Sep 4;10(1):275.

318 31. Sharma S, Dash PK, Agarwal S, Shukla J, Parida MM, Rao PVL. Comparative

319   complete genome analysis of dengue virus type 3 circulating in India between 2003 and

320   2008. J Gen Virol. 2011 Jul;92(Pt 7):1595–600.

321 32. Dash PK, Parida MM, Saxena P, Abhyankar A, Singh C, Tewari K, et al. Reemergence

322   of dengue virus type-3 (subtype-III) in India: Implications for increased incidence of

323   DHF & DSS. Virol J. 2006 Jul 6;3:55.

324 33. Messer WB, Gubler DJ, Harris E, Sivananthan K, de Silva AM. Emergence and Global

325   Spread of a Dengue Serotype 3, Subtype III Virus. Emerg Infect Dis. 2003

326   Jul;9(7):800–9.

327